U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07351864) titled 'Finerenone Plus SGLT2 Inhibitors in Heart Failure' on Dec. 28, 2025.
Brief Summary: The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure.
The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone.
Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess ...